Eugia Pharma Receives USFDA Approval for Cisatracurium Besylate Injection USP, 20 mg/10 mL Multiple-Dose Vials

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cisatracurium Besylate Injection USP, 20 mg/10mL MDV.

Indications for this product include adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age;
to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU; to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older.

Refer to package insert for full prescribing information.